maritide glp-1 Once Monthly Weight Loss Drug Shows High Discontinuation Rates in Phase II Trial Conjugation of GLP-1 peptide analog

Lack of regulatory guidance: Clinicians must obtain informed consent and monitor closely for safety, tolerability, and efficacy

Jubaidi FF, Zainalabidin S, Taib IS, Abdul Hamid Z, Mohamad Anuar NN, Jalil J, Mohd Nor NA, Budin SB (2022) The role of PKC-MAPK signalling pathways in the development of hyperglycemia-induced cardiovascular complications

The hypertrophic response to resistance training is not drug-specific

Theres also the danger of patients regaining the weight or, worse, suffering an AUD relapse when they either choose to go off the drug or have no choice but to go off, due to, say, an employment change and loss of insurance coverage for the medication